BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 15749643)

  • 1. [Hormone therapy in breast cancer: the end of tamoxifen?].
    Delozier T
    Bull Cancer; 2005 Feb; 92(2):142-50. PubMed ID: 15749643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolution of adjuvant endocrine therapy: developments since St Gallen 2005.
    Smith IE; Arnedos M
    Breast; 2007 Dec; 16 Suppl 2():S4-9. PubMed ID: 17764939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant endocrine therapy for early breast cancer.
    Andreetta C; Smith I
    Cancer Lett; 2007 Jun; 251(1):17-27. PubMed ID: 17150303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
    El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
    Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
    Singh Ranger G
    J Clin Pharm Ther; 2005 Aug; 30(4):313-7. PubMed ID: 15985044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT; Robert NJ
    Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
    Buzdar A; Chlebowski R; Cuzick J; Duffy S; Forbes J; Jonat W; Ravdin P
    Curr Med Res Opin; 2006 Aug; 22(8):1575-85. PubMed ID: 16870082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Aromatase inhibitors in the adjuvant therapy of breast cancer].
    Bauerschlag D; Schem C; Maass N; Jonat W
    Gynakol Geburtshilfliche Rundsch; 2005 Jun; 45(3):132-6. PubMed ID: 15990437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant endocrine therapy for perimenopausal women with early breast cancer.
    Ortmann O; Cufer T; Dixon JM; Maass N; Marchetti P; Pagani O; Pronzato P; Semiglazov V; Spano JP; Vrdoljak E; Wildiers H
    Breast; 2009 Feb; 18(1):2-7. PubMed ID: 19036588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A practical overview of aromatase inhibitors in postmenopausal women with hormone receptor-positive breast cancer.
    Younus J; Vandenberg TA
    Bull Cancer; 2005 Apr; 92(4):E39-44. PubMed ID: 15888383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors.
    Fentiman IS
    Int J Clin Pract; 2006 Jun; 60(6):689-93. PubMed ID: 16805754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying menopause in breast cancer patients: considerations and implications.
    Clemons M; Simmons C
    Breast Cancer Res Treat; 2007 Aug; 104(2):115-20. PubMed ID: 17061039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant endocrine therapy in premenopausal women with breast cancer.
    González Martín A; de la Cruz S; Márquez R
    Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():43-7. PubMed ID: 20711666
    [No Abstract]   [Full Text] [Related]  

  • 16. [The use of GnRH analogues in early and advanced breast carcinomas].
    Ségura C; Avenin D; Gligorov J; Selle F; Estéso A; Beerblock K; Emile G; Do Huyen N; Lotz JP
    Gynecol Obstet Fertil; 2005 Nov; 33(11):914-9. PubMed ID: 16246613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current status of adjuvant endocrine therapy for hormone responsive breast cancer].
    Ikeda T; Jinno H; Masamura S; Matsui A; Tajima G; Hohjoh T; Tokura H; Mitsui Y; Asaga S; Muto T; Fujiwara K; Kitajima M
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):902-8. PubMed ID: 11478138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.
    Wheler J; Johnson M; Seidman A
    Semin Oncol; 2006 Dec; 33(6):672-80. PubMed ID: 17145347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time?
    Montagna E; Cancello G; Colleoni M
    Cancer Treat Rev; 2013 Dec; 39(8):886-90. PubMed ID: 23725877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to endocrine therapy for breast cancer.
    Chlebowski RT; Geller ML
    Oncology; 2006; 71(1-2):1-9. PubMed ID: 17344666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.